Astrazeneca Pharma India Shows Strong Financial Growth and Positive Technical Trends

Astrazeneca Pharma India has recently undergone an evaluation adjustment, reflecting a shift in its underlying technical trends. The stock's technical indicators have shown a transition, with the MACD and Bollinger Bands signaling a bullish outlook on both weekly and monthly bases. This adjustment comes in light of the company's strong performance metrics, including a notable return on equity of 20.34% and a low debt-to-equity ratio, which stands at zero.
In terms of financial performance, Astrazeneca Pharma India reported a significant increase in profit after tax, reaching Rs 118.57 crore, which represents a growth of 39.08% over the last six months. Additionally, the company achieved its highest net sales for a quarter at Rs 526.31 crore, alongside a profit before tax of Rs 63.82 crore, marking a 20.1% increase compared to the previous four-quarter average.

The stock has consistently outperformed the BSE500 index over the past three years, with a remarkable 32.05% return in the last year alone. This performance, coupled with the company's strong management efficiency and positive results over the last three consecutive quarters, underscores its robust market position.

Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.